Psychosis Market Report 2026

Psychosis Market Overview

• Psychosis market size has reached to $10.46 billion in 2025 • Expected to grow to $13.7 billion in 2030 at a compound annual growth rate (CAGR) of 5.5% • Growth Driver: Increasing Cases of Mental Health Conditions Driving The Market Growth • Market Trend: The Increasing Demand For Biologics Fueling The Growth Of The Market Due To Rising Adoption Of Targeted And Personalized Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Psychosis Market?

Psychosis is a mental health condition where individuals lose touch with reality, experiencing hallucinations, delusions, and disorganized thinking. It is a symptom of various mental illnesses rather than a disorder itself. Early detection improves treatment outcomes, and effective care through medication, therapy, and support can help individuals regain stability. The main types of products for psychosis are tablets, capsules, and injections. Tablets are convenient, precisely dosed oral medications widely used for psychosis treatment to ensure consistent drug levels. The various disease types include schizophrenia, bipolar disorder, unipolar depression, dementia, and others. The product is distributed through several distribution channels, including online and offline, and used by various end-users, such as hospitals, healthcare clinics, specialty clinics, and others.

What Is The Psychosis Market Growth Forecast?

The psychosis market size is expected to see strong growth in the next few years. It will grow to $13.7 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing investment in novel antipsychotic drug development, rising focus on early-stage psychosis management, expansion of community-based mental health services, growing adoption of digital therapeutics, increasing demand for long-term disease management. Major trends in the forecast period include increasing use of long-acting injectable antipsychotics, rising adoption of early intervention programs, growing focus on integrated care models, expansion of digital monitoring tools for psychosis, enhanced emphasis on personalized treatment plans.

Global Psychosis Market Segmentation

1) By Product: Tablet, Capsule, Injection 2) By Disease Type: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Disease Types 3) By Distribution Channel: Online, Offline 4) By End-User: Hospitals, Healthcare Clinics, Speciality Clinics, Other End-Users Subsegments: 1) By Tablet: Antipsychotic Tablets, Mood Stabilizer Tablets 2) By Capsule: Antipsychotic Capsules, Antidepressant Capsules 3) By Injection: Long-acting Injectable Antipsychotics, Short-acting Injectable Antipsychotics

What Is The Driver Of The Psychosis Market?

The increasing cases of mental health conditions are expected to propel the growth of the psychosis market going forward. Mental health conditions are disorders that impact a person's mood, thinking, behavior, and overall mental well-being. The increasing cases of mental health conditions are due to rising stress levels, lifestyle changes, social isolation, economic pressures, and genetic predisposition. Psychosis treatment supports patients suffering from mental health issues through early diagnosis, medical intervention, and specialized treatments, leading to increased use of antipsychotic medications and therapy options. For instance, in May 2024, according to the American Psychiatric Association, a US-based professional organization of psychiatrists and trainee psychiatrists, 43% of adults reported experiencing higher levels of anxiety compared to the previous year, increasing from 37% in 2023 and 32% in 2022. Therefore, the increasing cases of mental health conditions are driving the growth of the psychosis industry.

Key Players In The Global Psychosis Market

Major companies operating in the psychosis market are Pfizer Inc., Johnson And Johnson, AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Inc., Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co., Dr Reddys Laboratories Ltd., Lundbeck AS, Gedeon Richter, Alkermes, Supernus Pharmaceuticals, Acadia Pharmaceuticals, Mapi Pharma, Astellas Pharma Inc., Newron Pharmaceuticals SpA, BioXcel Therapeutics, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Zydus Lifesciences Ltd.

Global Psychosis Market Trends and Insights

Major organizations operating in the psychosis market are focusing on developing advanced patient-voice and data-collection initiatives to improve service design, inform policy decisions, and enhance recovery-oriented care. Patient-voice initiatives enable individuals with lived experience and their families to directly share needs, challenges, and outcomes through structured surveys and research, supporting data-driven advocacy and more effective system reforms. For instance, in November 2025, Shine, an Ireland-based national mental health organization, in collaboration with Mental Health Reform, an Ireland coalition on mental health, and the HSE National Clinical Programme for Early Intervention in Psychosis (EIP), launched the 2025 National Survey of the Experiences of People Living with Psychosis. The initiative collects firsthand insights from people with psychosis and their families to identify real-world experiences in accessing care, highlight systemic gaps and stigma, and guide improvements in national policy, investment in specialist early intervention services, and expansion of community-based and crisis support options.

What Are Latest Mergers And Acquisitions In The Psychosis Market?

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical industry company, acquired Karuna Therapeutics for $14 billion. The acquisition is designed to bolster Bristol Myers Squibb's neuroscience portfolio by incorporating KarXT, a novel antipsychotic, and broadening its pipeline with potential therapies for schizophrenia, Alzheimer's disease, and other mental health conditions. Karuna Therapeutics is a US-based biopharmaceutical company that manufactures psychosis drugs.

Regional Outlook

North America was the largest region in the psychosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Psychosis Market?

The psychosis market consists of sales of transdermal patches, nasal sprays, intravenous (IV) infusions, long-acting injectable (LAI) implants, and inhalable formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Psychosis Market Report 2026?

The psychosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the psychosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.